Effects of TNF antagonists on immune and neuroendocrine system

Abstract Views: 1063
PDF: 679
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


In the article, the literature on the effects of TNFa-antagonists (etanercept, infliximab and adalimumab) on the immune system is reviewed. These biologic agents are employed in chronic inflammatory diseases such as rheumatoid arthritis, seronegative spondyloarthritides, as well as psoriasis and Crohn’s disease. The differences of these drugs, testified by the different effects on the immune response, are discussed. These molecules exert their effect through cytokine inhibition, but they present striking differences since they can modulate macrophage activity, T cells apoptosis, leukocyte migration, and angiogenesis to a different degree. Some studies showed that these agents also affect the hypothalamo- pituitary-adrenal axis. The potential immunogenicity of these biologic agents is also discussed.



PlumX Metrics


Download data is not yet available.


How to Cite

Valesini, G., & Cutolo, M. (2005). Effects of TNF antagonists on immune and neuroendocrine system. Reumatismo, 57(s4), 3–7. https://doi.org/10.4081/reumatismo.2005.4s.3